Recalling all 24 OTC eye-drop lines after an extortion threat (2000)
Emptying the shelves before anyone was harmed
What makes this decision unusual is that Santen moved not because a fault had been found in its own product, but because a crime had been announced from outside. Whether anything had actually been introduced into the bottles was unknown, and not a single case of harm was ever reported. Santen nonetheless declined to narrow the recall to particular lots, covered all 24 products shipped since February 1998, and began pulling them the day after the threat arrived. It was a decision to take the goods that carried its revenue off the shelves itself, with nothing confirmed.
Contemporary opinion split. Some cited it as a model response to a crisis brought in from outside; others objected that a total recall would set a precedent, forcing the same answer every time a similar threat was made. Both readings have a case, and no trace survives of Santen weighing the two outcomes at the time. What is on record is that two years after the recall began on 15 June 2000, the company was counted among the sixty listed firms that had gone through the twelve post-bubble years without a single decline in sales.
Read the full dossier in Japanese →
The Japanese edition carries the complete record of this decision — the situation that forced it, the options weighed, what actually followed, and the sources behind every claim.
Other key decisions at Santen Pharmaceutical
Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; the revenue chart is shown in yen. Exchange rates & sources — the full ¥/US$ table →
Disclaimer
- This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
- Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
- Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
- Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
- Company names, logos and other marks belong to their respective owners.
Data API
Santen Pharmaceutical’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.
Full specification →
| Method | Endpoint | Returns |
|---|---|---|
| GET | /api/companies.json | All companies |
| GET | /api/4536/manifest.json | Resource index |
| GET | /api/4536/history.json | History overview |
| GET | /api/4536/timeline.json | Chronology |
| GET | /api/decisions.json | All management decisions (index) |
| GET | /api/4536/decisions.json | Management decisions (index) |
| GET | /api/4536/decisions/{slug}.json | One decision (full dossier) |
| GET | /api/4536/executives.json | Executives |
| GET | /api/4536/shareholders.json | Major shareholders |
| GET | /api/4536/financials.json | Financial statements |
| GET | /api/4536/financials-longterm.json | Long-term results |
| GET | /api/4536/segments.json | Business segments |
| GET | /api/4536/regions.json | Sales by region |
| GET | /api/4536/workforce.json | Workforce |